Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02942095 · ClinicalTrials.gov registry record · Phase 1
Study of Ixazomib and Erlotinib in Solid Tumors
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02942095: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT02942095 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02942095, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of the combination of ixazomib and erlotinib that can be given to patients with advanced solid tumors. The safety of these drugs will also be studied. This is an investigational study. Erlotinib is FDA approved and commercially available to treat non-small cell lung cancer, but its use in advanced solid cancer is considered investigational. Ixazomib is FDA approved. The study doctor can explain how the study drugs are designed to work. Up to 36 patients will take part in this study. All will be enrolled at MD Anderson.
Primary Outcome
MTD defined by dose limiting toxicities (DLTs) that occur during the first cycle. Dose limiting toxicity (DLT) defined as 1. Any Grade 3 or 4 non-hematologic toxicity as defined in the NCI CTCAE. 2. Any Grade 4 hematologic toxicity lasting two weeks or longer (as defined by the NCI-CTCAE), despite supportive care. 3. Grade 4 nausea, vomiting or diarrhea \> 5 days despite maximum anti-nausea regimens.
Interventions
- DRUG Erlotinib
- DRUG Ixazomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2017-03-06 |
| Est. Completion | 2022-12-07 |
| Phase | Phase 1 |
What the finished NCT02942095 record still lists
NCT02942095 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Erlotinib is the first listed.
NCT02942095 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02942095 about?
NCT02942095 is a clinical study titled "Study of Ixazomib and Erlotinib in Solid Tumors". The goal of this clinical research study is to find the highest tolerable dose of the combination of ixazomib and erlotinib that can be given to patients with advanced solid tumors. The safety of these drugs will also be studied. This is an investigational study. Erlotinib is FDA approved and comme...
What is the current status of trial NCT02942095?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2017-03-06. Estimated completion is 2022-12-07.
What interventions are being tested in trial NCT02942095?
The interventions under investigation include: Erlotinib (DRUG), Ixazomib (DRUG).
Who is sponsoring clinical trial NCT02942095?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02942095's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI